ClinicalTrials.gg
Not yet recruitingNCT07436871Updated Feb 27, 2026

Comparison of Visual Outcomes and Patient Satisfaction in Mild to Moderate Glaucoma Patients Undergoing Cataract Surgery With EDOF Versus Monofocal IOLs

An interventional study of Cataract surgery (Monofocal intraocular lens implantation) and cataract surgery (Extended depht of focus intraocular lens implantation) in GLAUCOMA 1, OPEN ANGLE, D (Disorder) and Cataract, sponsored by OMIQ Research. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by OMIQ Research · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cataract is the leading cause of reversible vision loss, while glaucoma remains the primary cause of irreversible blindness, often impairing contrast sensitivity (CS), glare tolerance, and dark adaptation. These visual challenges are particularly relevant when selecting intraocular lenses (IOLs) for glaucoma patients undergoing cataract surgery.

Monofocal IOLs are the safest and most commonly used option for glaucoma patients due to their optical simplicity and low incidence of photic phenomena, though they do not provide spectacle independence for near or intermediate vision. Multifocal IOLs (MFIOLs), while offering greater spectacle independence, are relatively contraindicated in glaucoma due to increased visual disturbances like glare and halos.

Extended Depth of Focus (EDOF) IOLs offer an intermediate solution, using advanced optics to provide a continuous range of vision and fewer photic disturbances than MFIOLs. EDOF lenses have demonstrated good uncorrected distance and intermediate visual acuity in patients with mild to moderate glaucoma, with promising CS outcomes and high patient satisfaction. However, findings on CS performance remain inconsistent across studies.

Given these considerations, this study seeks to determine whether EDOF IOLs can be a viable alternative to monofocal lenses in glaucoma patients, potentially expanding their options for spectacle independence without compromising visual quality. The trial, conducted at OMIQ (Barcelona), will directly compare an EDOF IOL and a monofocal IOL made from the same material to assess their effects on visual acuity, contrast sensitivity, and photic phenomena in this specific patient population.

Read the detailed description

While cataract is the most prevalent cause of reversible loss of vision, glaucoma remains the leading cause of irreversible blindness, characterized by a progressive optic neuropathy with degeneration of retinal ganglion cells and visual field loss. Glaucoma negatively affects low-luminance contrast sensitivity, glare symptoms, and dark adaptation time more frequently than any other domain. Therefore, when choosing the type of lens to implant in these patients, concerns arise regarding contrast sensitivity (CS) loss and subjective visual disturbances, which may be more debilitating and can also be a limitation when choosing IOLs.

Monofocal IOLs have been shown to be the safest IOL choice for patients with glaucoma. Multifocal IOLs provide spectacle independence but, due to the technology used combined with the pathological changes in glaucoma, tey can cause more visual disturbances, which makes them a relative contraindication in eyes with glaucoma.

Recent studies have demonstrated that EDOF IOLs can be safely be implanted in eyes with mild, pre-perimetric open-angle glaucoma with favourable uncorrected distance and intermediate visual acuity outcomes. Additionally, contrast sensitivity measurements also have been shown to be favourable in this patients and satisfactory spectacle independence and patient satisfaction in the subjective questionnaire.

However, it is yet unknown if EDOF IOLs could be an equal or a better option in patients suffering from cataracts and glaucoma, compared to a Monofocal lens made of the same material, since this could provide wider options when choosing the IOL and could offer spectacle independence for intermediate and distant vision for these patients.

Rationale and positioning with regard to the state-of-the-art Cataract surgery is one of the most performed surgeries worldwide, where the natural lens of the eye is removed and replaced by an artificial intraocular lens (IOL) with the aim of replacing its functions of focusing on objects at different distances. While cataract is the most prevalent cause of reversible loss of vision, glaucoma remains the leading cause of irreversible blindness, characterized by a progressive optic neuropathy with degeneration of retinal ganglion cells and visual field loss. It is estimated that one in five people undergoing cataract surgery have glaucoma or ocular hypertension, with the incidence of both cataract and glaucoma increasing with age.

Glaucoma negatively affects low-luminance contrast sensitivity, glare symptoms, and dark adaptation time and extent. Patients report problems with lighting and dark adaptation more frequently than any other domain. These problems worsen with progressing visual field loss. Some studies have reported that early-stage glaucoma patients experience significantly more difficulties in low-luminance or changing lighting conditions than age-matched controls. Therefore, when choosing the type of lens to implant in these patients, concerns arise regarding contrast sensitivity (CS) loss and subjective visual disturbances such as glares and haloes, which may be more debilitating and may be also a limitation when choosing certain IOLs.

Currently, there are four main groups of IOLs: monofocal, enhanced monofocal, extended depth of focus (EDOF), and multifocal lenses. All of them provide different types of vision with different types of optical technology, which can make the patient to be more or less a candidate to wear them.

Monofocal IOLs provide excellent outcomes for distant vision, with the benefit of generally low cost and low frequency of photic phenomena such as glares and haloes.Therefore, they are the safest IOL choice for patients with pre-existing ocular pathology, like glaucoma, as they do not split light. However, as they only provide one focus point, they fail to deliver spectacle independence for near and intermediate vision.

Compared with traditional monofocal IOLs, premium IOLs, like Multifocal (MF) and Extended Depht-of-Focus (EDOF), offer the benefit of better unaided visual acuity, greater spectacle independence, and higher patient satisfaction.

MFIOLs, come in varying optical designs, such as diffractive, refractive, bifocal, trifocal, or hybrid IOLs, and provide multiple focal points, which allows the patient to see at different distances. However, pathological changes in glaucoma may also potentially interact with the optical effects of MFIOLs, as they tend to cause more halo or glare symptoms due to light scattering at the transitional zone between the distant and near focus of the lens, fact that makes them a relative contraindication in eyes with glaucoma.

EDOF IOLs use a recent technology that creates a single elongated focal point to enhance depth of focus and range of vision, effectively providing satisfactory near and intermediate vision while addressing limitations of MFIOLs, including negative photic phenomena such as glares and haloes. In addition, they also have provided superior intermediate and near vision and a similar visual disturbance profile compared with an aspheric monofocal IOL.

They enhance correction of chromatic aberration and maintain good CS that may be comparable to that of monofocal IOLs. Due to this characteristics, this type of lenses may be an option for glaucoma patients.

EDOF IOLs' behaviour is still not well understood as there have been conflicting results regarding CS outcomes. Certain studies have demonstrated a decrease in CS in eyes with EDOF IOLs under scotopic conditions, compared to eyes with monofocal IOLs while other studies reported no significant difference, and some others reported that EDOF IOLs performed significantly better than trifocal IOLs under both photopic and scotopic conditions. However, new EDOF IOLs have appeared safe and efficacious when implanting it patients with early to moderate bilateral glaucoma, warranting further studies in this population.

Today, choosing a monofocal IOL in patients with glaucoma is the most recommended option and the safest one, given the lack of interference of its optical technology with the optico-pathological changes produced by glaucoma. Most IOLs today use a new type of optical technology that allows the patient to be spectacles independent or independent for near and intermediate vision, which is a great advantage. However, this type of technology is not well tolerated by glaucoma patients, meaning that they have fewer options when choosing an IOL compared to the standard population, that they cannot benefit from this premium technology, and that, therefore, it makes them dependent on glasses for near and intermediate vision. However, despite controversies, EDOF IOLs have proven to be somehow effective in glaucoma patients.This study aims to find out if an EDOF IOL could help to open up a door for these patients, by analysing its behavior compared to a monofocal lens made of the same material and by obtaining the effect of this lens on the visual acuity in at different distances and, additionally, to evaluate the CS and the photopic phenomena like glares and halos.

02

Conditions studied

  • GLAUCOMA 1, OPEN ANGLE, D (Disorder)
  • Cataract

Keywords

  • cataract surgery
  • Extended depth of focus intraocular lens
  • Primary open-angle glaucoma
03

In context

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

This study's planned enrollment of 74 is close to the median of 79 across 1,094 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

OMIQ Research is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of any sex aged 18 years or older willing to participate and sign the form.
  • cataracts in both eyes.
  • Patients clinically diagnosed of primary open angle glaucoma (POAG) in both eyes.
  • Early to moderate POAG, as defined by a mean deviation in the Humphrey Visual Field Analyzer (HFA) no worse than ≤ -12 dB and worse ≥ -2 dB at least in one eye, using a 24-2 SITA standard strategy
  • Two visual field tests without progression and stability of RNFL in Optical Coherence Tomography (OCT) thickness remaining same or less than 10 um in the previous 6 months, with pharmacologically controlled IOP in both eyes \<21mmHg.
  • Potential for post-surgery monocular distance corrected visual acuity of ≤ 0.10 LogMAR.
  • Normal corneal topography.
  • Able to attend all study visits.

Exclusion criteria

Exclusion criteria:

  • Patients with uncontrolled glaucoma, defined as those with an IOP ≥21 mm Hg despite maximal medical therapy, requiring glaucoma surgery and/or laser in either eye in the next year.
  • Pre-surgery refractive error requiring IOL implantation beyond the commercially available range.
  • Patients with a not reliable visual field, a VFI ≤ 60% or defects of ≤ 10 dB in the 4 central points of the visual field.

Any other form of glaucoma (pseudoexfoliative, severe forms of pigmentary, primary angle closure glaucoma, etc.), ocular hypertension, zonular instability or possible intuitive lens decentration after surgery.

  • Patients with any previous glaucoma surgery or any other ocular surgery that can affect the results, or any ocular surgery in the previous six months.
  • Any other ocular pathology that can affect the results.
  • Use of topic or systemic medication that may affect vision
  • Unable to cooperate to obtain consistent testing results.
  • Participation in any other trial during or within 30 days of the screening visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
74 participants (estimated)

Study arms

  • Active comparator
    cataract, glaucoma, monofocal intraocular lens

    Bilateral cataract surgery in patients with primary open-angle glaucoma receiving monofocal intraocular lens implantation (n = 37 in this study arm).

    Procedure: Cataract surgery (Monofocal intraocular lens implantation)

  • Experimental
    cataract, glaucoma, Extended range of focus intraocular lens

    Bilateral cataract surgery in patients with primary open-angle glaucoma receiving extended range of focus intraocular lens implantation (n = 37 in this study arm).

    Procedure: cataract surgery (Extended depht of focus intraocular lens implantation)

Interventions

  • ProcedureCataract surgery (Monofocal intraocular lens implantation)

    This intervention consists of bilateral cataract surgery, a microsurgical procedure in which the eye's natural, clouded lens is removed and replaced with an artificial intraocular lens (IOL) to restore clear vision. In this study, patients with early to moderate primary open-angle glaucoma (POAG) will receive either a monofocal or extended depth-of-focus (EDOF) IOL. The surgical technique involves standard phacoemulsification through a small corneal incision, followed by IOL implantation into the capsular bag. What distinguishes this intervention from others is the glaucoma-specific population, with perioperative protocols designed to minimize intraocular pressure fluctuations and preserve optic nerve function. Additionally, both IOLs share the same material and platform, allowing for an isolated comparison of optical design effects.

  • Procedurecataract surgery (Extended depht of focus intraocular lens implantation)

    This intervention consists of bilateral cataract surgery, a microsurgical procedure in which the eye's natural, clouded lens is removed and replaced with an artificial intraocular lens (IOL) to restore clear vision. In this study, patients with early to moderate primary open-angle glaucoma (POAG) will receive either a monofocal or extended depth-of-focus (EDOF) IOL. The surgical technique involves standard phacoemulsification through a small corneal incision, followed by IOL implantation into the capsular bag. What distinguishes this intervention from others is the glaucoma-specific population, with perioperative protocols designed to minimize intraocular pressure fluctuations and preserve optic nerve function. Additionally, both IOLs share the same material and platform, allowing for an isolated comparison of optical design effects.

06

What researchers measure

Primary outcomes

  1. Binocular distance-corrected intermediate visual acuity (DCIVA)

    The comparison of the binocular, distance-corrected intermediate visual acuity (bDCIVA) between groups at month 3. For the visual acuity assessments in this study, measurements will be expressed using LogMAR (Logarithm of the Minimum Angle of Resolution) units. The LogMAR scale provides a standardized way to quantify visual acuity, with higher values indicating worse vision. The range of LogMAR units typically spans from -0.3 (indicating excellent vision) to +2.0 (indicating severe visual impairment), ensuring a comprehensive evaluation of participants' visual performance.

    Time frame: 3 months

Secondary outcomes

  1. bUDVA, bUIVA, bUNVA, bDCVA and bDCNVA

    The binocular, uncorrected and distance-corrected distance, intermediate (66 cm) and near (40 cm) visual acuities (bUDVA, bUIVA, bUNVA, bDCVA and bDCNVA, respectively) in groups at month 3. For the visual acuity assessments in this study, measurements will be expressed using LogMAR (Logarithm of the Minimum Angle of Resolution) units. The LogMAR scale provides a standardized way to quantify visual acuity, with higher values indicating worse vision. The range of LogMAR units typically spans from -0.3 (indicating excellent vision) to +2.0 (indicating severe visual impairment), ensuring a comprehensive evaluation of participants' visual performance.

    Time frame: 3 months

  2. mUDVA, mUIVA, mUNVA, mDCDVA, mDCIVA and mDCNVA

    he monocular, uncorrected and corrected distance, intermediate (66 cm) and near (40 cm) visual acuity (mUDVA, mUIVA, mUNVA, mDCDVA, mDCIVA and mDCNVA, respectively) in groups at month 3. For the visual acuity assessments in this study, measurements will be expressed using LogMAR (Logarithm of the Minimum Angle of Resolution) units. The LogMAR scale provides a standardized way to quantify visual acuity, with higher values indicating worse vision. The range of LogMAR units typically spans from -0.3 (indicating excellent vision) to +2.0 (indicating severe visual impairment), ensuring a comprehensive evaluation of participants' visual performance.

    Time frame: 3 months

  3. Defocus curve

    Defocus curve performance at month 3 The defocus curve typically uses diopters (D) as its unit of measurement. Diopters quantify the optical power of a lens and are used to assess how well a person's vision performs across different focus levels (with a scale that typically ranges from -5.00 D to +2.00 D), indicating the clarity of vision at varying distances.

    Time frame: 3 months

  4. Mesopic and photopic contrast sensitivity

    Distance-corrected binocular contrast sensitivity in photopic and mesopic conditions before the surgery and at month 3. Contrast sensitivity is typically measured using the logarithm of contrast sensitivity (log CS), with a scale that generally ranges from 0 to 3.0. Values close to 3.0 indicate excellent contrast sensitivity, while values closer to 0 suggest significantly diminished contrast sensitivity. In some tests, results may also be reported as decimal values or percentages, where higher values correspond to a better ability to detect low-contrast stimuli. This comprehensive scale allows for an effective evaluation of a person's visual performance in varying lighting and contrast conditions.

    Time frame: 3 months

  5. Visual field stability

    Change in visual field index (VFI) before the surgery and at month 3. The Visual Field Index (VFI) is typically measured as a percentage, with a scale ranging from 0% to 100%. A VFI of 100% indicates a full visual field with no loss, while lower percentages represent varying degrees of visual field loss.

    Time frame: 3 months

  6. OCT stability

    Changes in mean central subfield macular and mean peripapillary thickness and sector peripapilar retinal nerve fiber layer and macular ganglion cell layer thickness before the surgery and at month 3. Optical Coherence Tomography (OCT) of the optic nerve is typically measured in micrometers (µm). This measurement assesses the thickness of the retinal nerve fiber layer (RNFL) and other structures of the optic nerve head, together with macular thickness. The scale for RNFL thickness can vary depending on the specific protocol or software used, but it generally ranges from approximately 50 µm to 150 µm or more, with lower values indicating potential nerve damage or thinning associated with conditions like glaucoma.

    Time frame: 3 months

  7. Light distorsion index (LDI)

    The quantification of the presence of halos with Light distortion index (LDI) at month 3. The Light Distortion Index (LDI) is typically measured in arbitrary units (AU). This index quantifies the degree of light distortion that occurs as light passes through the optical system, often used to assess the quality of vision and optical performance. The scale for LDI can vary but usually encompasses a range where lower values indicate minimal distortion (better optical quality) and higher values indicate greater distortion (poorer optical quality).

    Time frame: 3 months

  8. Patient satisfaction and spectacle independence

    The spectacle independence assessed via the questionnaire Cataract Questionnaire (CATQUEST) before the surgery and at month 3. The CATQUEST score generally ranges from 0 to 100, where a score of 0 indicates the worst visual function and quality of life, while a score of 100 represents the best possible vision and quality of life. This scale allows for a subjective assessment of how well a patient perceives their visual abilities and the difficulties they experience in daily tasks, helping to evaluate the effectiveness of treatment or intervention. Higher scores indicate better visual function and a more favorable quality of life related to vision.

    Time frame: 3 months

  9. Dysphotopsia

    The grade of dysphotopsia with Questionnaire of visual disturbances (QUVID) at month 3. The QUVID typically employs a Likert scale ranging from 0 to 4, where participants rate the severity or frequency of symptoms such as glare, halos, or light sensitivity. In this context, a score closer to 0 indicates minimal or no dysphotopsia, while higher scores (e.g., 3 or 4) reflect more significant disturbances.

    Time frame: 3 months

  10. Visual field stability

    Change in visual field mean deviation (MD) before the surgery and at month 3. The Mean Deviation (MD) in visual field testing is measured in decibels (dB). This value represents the average difference in sensitivity between the individual's threshold and the normal threshold for a range of points in the visual field. The scale for MD typically ranges from positive values (indicating better than average sensitivity) to negative values (indicating visual field loss). A higher positive value (e.g., +2 dB) suggests that the visual field is better than normal, while a more negative value (e.g., -12 dB) indicates greater degrees of visual field loss.

    Time frame: 3 months

  11. Patient satisfaction and spectacle independence

    Patient-Reported Spectacle Independence Questionnaire score (PRSIQ) before the surgery and at month 3. The PRSIQ usually employs a Likert scale, ranging from 0 to 5 or 1 to 5, where lower values indicate poorer visual quality or greater dissatisfaction and higher values indicate better visual quality or greater satisfaction. Each item in the questionnaire is rated based on the patient's experience, contributing to an overall score that reflects their perceived quality of vision and satisfaction with visual function.

    Time frame: 3 months

Other outcomes

  1. Safety endpoints

    The safety endpoints of the study will include IOP ≤ 25 mm Hg. The scale for intraocular pressure generally ranges from about 10 mmHg to 21 mmHg in healthy eyes, though values above 21 mmHg are often considered elevated. However, following certain surgical procedures, IOP may rise above 25 mmHg due to expected alterations in fluid dynamics within the eye and as a result of steroid therapy administered as a standard postoperative treatment.

    Time frame: up to 3 months

  2. Safety endpoints

    Anterior segment adverse event. Anterior segment analysis using a slit lamp is typically assessed without specific units of measurement, as it primarily involves visual and qualitative evaluations of the structures, by the physician, within the anterior segment of the eye.

    Time frame: up to 3 months

  3. Safety endpoints

    Posterior segment adverse event Posterior segment analysis using a slit lamp, often enhanced with specialized lenses, is primarily conducted through visual and qualitative evaluations by the physician, without the use of specific units of measurement. This examination focuses on assessing the various structures within the posterior segment of the eye. The findings are typically reported descriptively based on the physician's observations and assessments of the anatomical features and any abnormalities present.

    Time frame: up to 3 months

  4. Safety endpoints

    Visual field worsening Visual field worsening is generally measured using decibels (dB) in the context of perimetry tests, which quantify the sensitivity of the visual field at various points. Lower decibel values indicate poorer sensitivity and greater visual field loss. The Visual Field Index (VFI) is another important measurement used to assess visual field performance, typically expressed as a percentage ranging from 0% to 100%. A VFI of 100% indicates a full visual field with no loss, while lower percentages reflect varying degrees of visual field impairment.

    Time frame: up to 3 months

  5. Safety endpoints

    Endophthalmitis rates The rates of endophthalmitis are typically expressed as percentage rates or incidence rates. These rates represent the frequency of occurrences of endophthalmitis within a specific population or patient group, usually following cataract surgery or other ocular procedures. For example, the incidence of endophthalmitis might be reported as cases per 1,000 or 10,000 surgeries performed. Commonly cited rates of endophthalmitis following cataract surgery range from 0.05% to 0.3%, but this can vary based on factors such as surgical technique, use of prophylactic antibiotics, and patient characteristics.

    Time frame: up to 3 months

  6. Safety endpoints

    Systemic adverse events Systemic adverse events related to ocular treatments or surgeries are typically assessed and reported using various units of measurement, such as: * Incidence Rates: Often expressed as percentage rates or cases per 1,000 or 10,000 patients treated. For example, the incidence of systemic adverse effects might be reported as occurring in 0.5% to 2% of patients. * Severity Scales: The severity of systemic adverse effects may be classified using qualitative scales, such as mild, moderate, or severe, allowing for a standardized way to describe the impact of these effects on patient health. * Duration: In some cases, the duration of systemic adverse effects may be measured in units of time, such as days or weeks, to provide insight into the persistence of symptoms. By using these measurements, clinicians can evaluate the frequency and impact of systemic adverse effects following ocular treatments or interventions.

    Time frame: up to 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Feb 2027, 13 months later.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 13 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 27, 2026
StartEst.
Jan 31, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07436871
Lead sponsor
OMIQ Research
Responsible party
Idoia Goñi Guarro (MD, OMIQ Research) — Principal investigator
First posted
Feb 27, 2026
Start date
Jan 31, 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion